Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492500 · ClinicalTrials.gov registry record · Phase 2
A Study of Ponsegromab in People With Heart Failure
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 455
- Enrollment target
NCT05492500: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT05492500 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 455 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (242% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05492500, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 455 participants
- Enrollment target
Study Summary
The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find out if the study medicine is better than the placebo (an injection that looks like the study medicine but does not contain the active medicine) for treatment of symptoms related to heart failure. Participants will not know which treatment group they are assigned to. Most participants in this study will receive the study medicine or placebo by shots under the skin every four weeks. People may be able to participate in this study if they have heart failure. Participants will take part in this study for about 9 months. During this time participants will visit the study clinic once a month. A separate PK cohort within this clinical trial will receive open-label study medicine (Ponsegromab/PF-06946860) only. Participants in this open-label, PK cohort will not receive placebo. These participants will receive the study medicine by shots under the skin every four weeks. People may be able to participate in this study cohort if they also have heart failure. Participants will take part in the open-label, PK cohort for about 7 months.
Primary Outcome
KCCQ is a self-reported 23-item questionnaire that assessed health related quality of life (HRQL) in participants with heart failure (HF) over the past 2 weeks. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 (worst status) to 100 (best possible status). KCCQ total
Interventions
- DRUG Main cohort (Cohort A): Ponsegromab low dose
- DRUG Main cohort (Cohort A): Ponsegromab medium dose
- DRUG Main cohort (Cohort A): ponsegromab high dose
- OTHER Main cohort (Cohort A): Matched placebo
- DRUG Open-label, PK Cohort (Cohort B): ponsegromab low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2022-09-26 |
| Est. Completion | 2025-03-05 |
| Phase | Phase 2 |
Why NCT05492500 stopped before completion
NCT05492500 is an interventional study that assigns participants to a tested intervention. The registered 455 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (242% higher).
The record links to 0 conditions, and to 5 interventions - of which Main cohort (Cohort A): Ponsegromab low dose is the first listed.
NCT05492500 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05492500 about?
NCT05492500 is a clinical study titled "A Study of Ponsegromab in People With Heart Failure". The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find out if the study medicine is better than the placebo (an injection that l...
What is the current status of trial NCT05492500?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 455 participants. The study started on 2022-09-26. Estimated completion is 2025-03-05.
What interventions are being tested in trial NCT05492500?
The interventions under investigation include: Main cohort (Cohort A): Ponsegromab low dose (DRUG), Main cohort (Cohort A): Ponsegromab medium dose (DRUG), Main cohort (Cohort A): ponsegromab high dose (DRUG), Main cohort (Cohort A): Matched placebo (OTHER), Open-label, PK Cohort (Cohort B): ponsegromab low dose (DRUG).
Who is sponsoring clinical trial NCT05492500?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05492500's enrollment target sits among peer trials
455 85th of 2000 higher than 1,914 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
- NCT06079346 · 455 participants · Phase 2
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- NCT06504446 · 455 participants · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
- NCT06725030 · 455 participants
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI